Literature DB >> 9194150

Effects of kawain and dihydromethysticin on field potential changes in the hippocampus.

J Walden1, J von Wegerer, U Winter, M Berger, H Grunze.   

Abstract

1. The kava-pyrones kawain and dihydromethysticin are constituents of Piper methysticum which exert anticonvulsant, analgesic and anxiolytic properties. 2. In the present study the effect of these kava-pyrones were tested on field potential changes (fp) induced by omission of the extracellular Mg2+, recorded from the area CA1 and CA3 of the hippocampal slice preparation of guinea pigs. These fp are generated by an activation of NMDA receptors and voltage dependent calcium channels. 3. Kawain and dihydromethysticin reduced reversibly the frequency of occurrence of fp in a concentration range from 5 to 40 mumol/l and 10 to 40 mumol/l, respectively. 4. Reduction of the fp frequency after addition of subthreshold concentrations of 5 mumol/l kawain and 10 mumol/l dihydromethysticin indicated additive actions of both drugs. 5. Since the serotonin-1A agonist ipsapirone also exerts anxiolytic effects, subthreshold concentrations of kawain or dihydromethysticin were combined with a subthreshold concentration of ipsapirone in another set of experiments. Combining kawain and ipsapirone or dihydromethysticin and ipsapirone caused a reduction of the rate of fp to 0.76 and 0.81 of the baseline value, respectively. 6. The findings suggest that (i) single constituents of Piper methysticum may have additive actions, (ii) that the two components kawain and dihydromethysticin may enhance the effects of the anxiolytic serotonin-1A agonist ipsapirone and (iii) that activation of NMDA receptors and/or voltage dependent calcium channels may be involved in the elementary mechanism of action of some kava-pyrones.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9194150     DOI: 10.1016/s0278-5846(97)00042-0

Source DB:  PubMed          Journal:  Prog Neuropsychopharmacol Biol Psychiatry        ISSN: 0278-5846            Impact factor:   5.067


  6 in total

Review 1.  Plant-based medicines for anxiety disorders, part 2: a review of clinical studies with supporting preclinical evidence.

Authors:  Jerome Sarris; Erica McIntyre; David A Camfield
Journal:  CNS Drugs       Date:  2013-04       Impact factor: 5.749

Review 2.  Therapeutic potential of kava in the treatment of anxiety disorders.

Authors:  Yadhu N Singh; Nirbhay N Singh
Journal:  CNS Drugs       Date:  2002       Impact factor: 5.749

3.  Dihydromethysticin kavalactone induces apoptosis in osteosarcoma cells through modulation of PI3K/Akt pathway, disruption of mitochondrial membrane potential and inducing cell cycle arrest.

Authors:  Jun-Qi Dai; Yi-Gang Huang; Ai-Na He
Journal:  Int J Clin Exp Pathol       Date:  2015-05-01

4.  Kava for the treatment of generalised anxiety disorder (K-GAD): study protocol for a randomised controlled trial.

Authors:  Karen M Savage; Con K Stough; Gerard J Byrne; Andrew Scholey; Chad Bousman; Jenifer Murphy; Patricia Macdonald; Chao Suo; Matthew Hughes; Stuart Thomas; Rolf Teschke; Chengguo Xing; Jerome Sarris
Journal:  Trials       Date:  2015-11-02       Impact factor: 2.279

Review 5.  Kava as a Clinical Nutrient: Promises and Challenges.

Authors:  Tengfei Bian; Pedro Corral; Yuzhi Wang; Jordy Botello; Rick Kingston; Tyler Daniels; Ramzi G Salloum; Edward Johnston; Zhiguang Huo; Junxuan Lu; Andrew C Liu; Chengguo Xing
Journal:  Nutrients       Date:  2020-10-05       Impact factor: 5.717

6.  3D Imaging and metabolomic profiling reveal higher neuroactive kavalactone contents in lateral roots and crown root peels of Piper methysticum (kava).

Authors:  Yogini S Jaiswal; Aaron M Yerke; M Caleb Bagley; Måns Ekelöf; Daniel Weber; Daniel Haddad; Anthony Fodor; David C Muddiman; Leonard L Williams
Journal:  Gigascience       Date:  2020-09-22       Impact factor: 6.524

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.